rct
    2016
    High Quality

    Fludrocortisone for the prevention of vasovagal syncope: a randomized, placebo-controlled trial

    Sheldon R, Raj SR, Rose MS, Morillo CA, Krahn AD, Medina E, Talajic M

    Published in Journal of the American College of Cardiology

    Key Findings

    Fludrocortisone did not significantly reduce syncope recurrence in the intention-to-treat analysis, though a benefit appeared after dose stabilisation.

    Conclusions

    Mineralocorticoid therapy shows at best a marginal effect on fainting frequency.

    Limitations

    Underpowered; borderline primary result.

    Related Health Concerns

    Fainting

    Study Details

    Year:2016
    Sample Size:210
    Duration:52 weeks
    Quality Score:8/10

    Access Study

    View on DOIView on PubMedOriginal Source

    This information is for educational purposes only. Always consult a healthcare professional before starting any supplement regimen.